EP2861623A4 - Neuartige clec14a-spezifische antikörper und verwendungen davon - Google Patents
Neuartige clec14a-spezifische antikörper und verwendungen davonInfo
- Publication number
- EP2861623A4 EP2861623A4 EP13805033.1A EP13805033A EP2861623A4 EP 2861623 A4 EP2861623 A4 EP 2861623A4 EP 13805033 A EP13805033 A EP 13805033A EP 2861623 A4 EP2861623 A4 EP 2861623A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- new specific
- clec14a antibody
- clec14a
- antibody
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659654P | 2012-06-14 | 2012-06-14 | |
| PCT/KR2012/008618 WO2013187556A1 (en) | 2012-06-14 | 2012-10-19 | Novel antibody specific for clec14a and uses thereof |
| PCT/KR2013/005272 WO2013187724A1 (en) | 2012-06-14 | 2013-06-14 | Novel antibody specific for clec14a and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2861623A1 EP2861623A1 (de) | 2015-04-22 |
| EP2861623A4 true EP2861623A4 (de) | 2015-12-02 |
Family
ID=49758359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13805033.1A Withdrawn EP2861623A4 (de) | 2012-06-14 | 2013-06-14 | Neuartige clec14a-spezifische antikörper und verwendungen davon |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9751933B2 (de) |
| EP (1) | EP2861623A4 (de) |
| JP (1) | JP6129305B2 (de) |
| KR (1) | KR101760465B1 (de) |
| CN (1) | CN104903350B (de) |
| WO (2) | WO2013187556A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| GB201501004D0 (en) * | 2015-01-21 | 2015-03-04 | Cancer Rec Tech Ltd | Inhibitors |
| KR20200091499A (ko) * | 2015-05-06 | 2020-07-30 | 스니프르 테크놀로지스 리미티드 | 미생물 개체군 변경 및 미생물군 변형 |
| CA3015293A1 (en) * | 2016-03-15 | 2017-09-21 | Cancer Research Technology Limited | Chimeric antigen receptor |
| JP7501991B2 (ja) | 2016-03-15 | 2024-06-18 | キャンサー・リサーチ・テクノロジー・リミテッド | 抗体及び関連分子並びにその使用 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| US20190309074A1 (en) * | 2016-09-08 | 2019-10-10 | Woori Technologies Corporation | Deglycosylated antibody specifically binding to clec14a and uses thereof |
| GB201712733D0 (en) | 2017-08-08 | 2017-09-20 | Snipr Tech Ltd | Methods & cells |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| US20220275081A1 (en) * | 2018-10-17 | 2022-09-01 | Good T Cells, Inc. | Binding molecule specific for lrig-1 protein and use thereof |
| GB201914514D0 (en) * | 2019-10-08 | 2019-11-20 | Univ Birmingham | Treatment of osteopenia and/or osteoporosis |
| US12281161B2 (en) | 2021-07-28 | 2025-04-22 | Trustees Of Boston University | Polypeptides and uses thereof |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011027132A1 (en) * | 2009-09-03 | 2011-03-10 | Cancer Research Technology Limited | Clec14a inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP1235842A4 (de) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Gene des rns-interferenzweges als hilfsmittel der gezielten gentischen interferenz |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20040033495A1 (en) * | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| US9535075B2 (en) * | 2010-03-25 | 2017-01-03 | The Board Of Trustees Of The Leland Stanford Junior University | Protein and gene biomarkers for rejection of organ transplants |
-
2012
- 2012-10-19 WO PCT/KR2012/008618 patent/WO2013187556A1/en not_active Ceased
-
2013
- 2013-06-14 WO PCT/KR2013/005272 patent/WO2013187724A1/en not_active Ceased
- 2013-06-14 EP EP13805033.1A patent/EP2861623A4/de not_active Withdrawn
- 2013-06-14 US US14/407,756 patent/US9751933B2/en active Active
- 2013-06-14 CN CN201380043426.9A patent/CN104903350B/zh active Active
- 2013-06-14 JP JP2015517188A patent/JP6129305B2/ja active Active
- 2013-06-14 KR KR1020157000309A patent/KR101760465B1/ko active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011027132A1 (en) * | 2009-09-03 | 2011-03-10 | Cancer Research Technology Limited | Clec14a inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2861623A1 (de) | 2015-04-22 |
| CN104903350B (zh) | 2018-10-23 |
| US20150140001A1 (en) | 2015-05-21 |
| KR101760465B1 (ko) | 2017-07-24 |
| JP6129305B2 (ja) | 2017-05-17 |
| CN104903350A (zh) | 2015-09-09 |
| WO2013187556A1 (en) | 2013-12-19 |
| KR20150023665A (ko) | 2015-03-05 |
| JP2016503286A (ja) | 2016-02-04 |
| US9751933B2 (en) | 2017-09-05 |
| WO2013187724A1 (en) | 2013-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1061I2 (fr) | Anticorps anti-angptl3 et utilisations de ceux-ci | |
| FR23C1019I2 (fr) | Anticorps anti-complément c1s et utilisations de ceux-ci | |
| FR24C1019I2 (fr) | Anticorps anti-fcrn | |
| EP2879708A4 (de) | Anti-etbr-antikörper und immunkonjugate | |
| EP2822592A4 (de) | Spezifische tgf-1-antikörper und verfahren sowie verwendungen davon | |
| EP2533810A4 (de) | Cd20-antikörper und ihre verwendung | |
| EP2832856A4 (de) | Anti-lamp5-antikörper und verwendung davon | |
| EP2788377A4 (de) | Her3-antikörper und verwendungen davon | |
| EP2861622A4 (de) | Antiidiotypische anti-cd22-antikörper und verwendungen davon | |
| EP2794654A4 (de) | Anti-phf-tau-antikörper und ihre verwendungen | |
| EP2912065A4 (de) | Anti-komplement-c1s-antikörper und verwendungen davon | |
| EP2930240A4 (de) | Anti-folr1-antikörper | |
| EP2970505A4 (de) | Spezifische antikörper und verwendungen davon | |
| PT2922875T (pt) | Anticorpos anti-ceacam5 e suas utilizações | |
| EP2640854A4 (de) | Nc-rna und verwendung davon | |
| EP2836608A4 (de) | Tuberkulosebiomarker und verwendungen davon | |
| EP2841458A4 (de) | Modifizierte antikörperregionen und verwendung davon | |
| IL238227A0 (en) | Anti-c16orf54 antibodies and methods of use thereof | |
| EP2718325A4 (de) | Anti-psgl-1 antikörper und verwendungen davon | |
| EP2774914A4 (de) | N-benzylanilinderivat und seine verwendungen | |
| EP2888286A4 (de) | Antikörper gegen quetiapinhaptene und verwendung davon | |
| EP2918681A4 (de) | Fruchtbarkeitsgen und verwendungen davon | |
| EP2593475A4 (de) | Monoklonaler antikörper gegen addl und anwendungen davon | |
| EP2632952A4 (de) | Antikörper gegen sod1 und anwendungen davon | |
| EP2830660A4 (de) | Anti-sema4d-antikörper und epitope |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20141211 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20151102 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101AFI20151027BHEP Ipc: C07K 14/435 20060101ALI20151027BHEP Ipc: C07K 14/705 20060101ALI20151027BHEP Ipc: G01N 33/53 20060101ALI20151027BHEP Ipc: C12N 15/13 20060101ALI20151027BHEP Ipc: C07K 7/08 20060101ALI20151027BHEP Ipc: A61P 35/00 20060101ALI20151027BHEP Ipc: A61K 47/48 20060101ALI20151027BHEP Ipc: A61K 39/395 20060101ALI20151027BHEP Ipc: C07K 16/18 20060101ALI20151027BHEP |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/18 20060101ALI20160822BHEP Ipc: C07K 16/28 20060101AFI20160822BHEP Ipc: A61K 39/395 20060101ALI20160822BHEP Ipc: C12N 15/13 20060101ALI20160822BHEP Ipc: G01N 33/53 20060101ALI20160822BHEP Ipc: C07K 14/435 20060101ALI20160822BHEP Ipc: C07K 14/705 20060101ALI20160822BHEP Ipc: C07K 7/08 20060101ALI20160822BHEP Ipc: A61P 35/00 20060101ALI20160822BHEP Ipc: A61K 47/48 20060101ALI20160822BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20161121 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SCRIPPS KOREA ANTIBODY INSTITUTE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20170404 |